Survodutide
Dual GLP-1/glucagon agonist in development
Overview
Survodutide is a dual GLP-1 and glucagon receptor agonist that combines appetite suppression with direct fat oxidation.
Key Information
Mechanism
Dual agonism of GLP-1 (appetite) and glucagon (fat oxidation, thermogenesis) receptors.
Benefits
- Up to 19% weight loss
- Dual GLP-1/glucagon mechanism
- Fat oxidation + appetite suppression
Side Effects
- Nausea
- Diarrhea
- Vomiting
Contraindications
- Not studied in pregnancy
Evidence Summary
Phase 2 showed up to 19% weight loss at 46 weeks. Phase 3 ongoing.
Research
Phase 2 showed up to 19% weight loss at 46 weeks.
View ResearchSafety
GI side effects similar to GLP-1 class.
Frequently Asked Questions About Survodutide
What is Survodutide?
Survodutide is a research peptide also known as BI 456906. Dual GLP-1/glucagon agonist in development It is studied for its potential therapeutic applications and is available from various research chemical vendors.
How does Survodutide work?
Dual agonism of GLP-1 (appetite) and glucagon (fat oxidation, thermogenesis) receptors.
What is the recommended dosage for Survodutide?
The commonly studied dosage range for Survodutide is 0.6-4.8 mg weekly. Dosage protocols vary based on research objectives. Always consult published studies and start with conservative amounts. Survodutide should only be used in controlled research settings.
Where can I buy Survodutide?
PepsReview indexes Survodutide pricing from multiple vendors. Check the Vendors tab above for a price comparison table showing cost per milligram, purity, COA status, and stock availability. Vendor reviews from real users are available on each vendor's profile page.
Is Survodutide legal?
US regulatory status: Investigational (Phase 3). The legal status of Survodutide varies by jurisdiction. In most countries, it is sold as a research chemical, not for human consumption. Always verify the legal status in your country before purchasing.
What are the side effects of Survodutide?
Reported side effects include: Nausea, Diarrhea, Vomiting. Always review safety data and published studies before use.
Key Research Papers on Survodutide
The following peer-reviewed studies and clinical trials are indexed in our research library for Survodutide. Each paper links to a detailed summary with key findings, study design, and publication metadata.
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial — Lancet Diabetes Endocrinol, 2024 (300 citations)
- Survodutide Once Weekly for the Treatment of Adults with Obesity — N Engl J Med, 2026 (200 citations)
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial — JACC Heart Fail, 2024 (40 citations)
Related Weight loss / Metabolic Peptides
Other peptides in the weight loss / metabolic category that may be of interest for comparative research:
No vendor prices yet
We don't have pricing data for this peptide yet.
Write a Review
Rating Breakdown
Based on 2 reviews.
Reviews
Participated in a trial. Lost 17% of body weight in 6 months. The glucagon component really helps with fat burning. Less nausea than pure GLP-1 agonists. Excited for approval.
Been on survodutide for 3 months, down 16 lbs. The GLP-1/glucagon dual mechanism gives good fat oxidation. Appetite suppression is decent but not as strong as tirzepatide. Looking forward to more data.
Community Discussions on Survodutide
Join the conversation in our peptide community forum. Real users share their survodutide experiences, dosing schedules, results, and tips.
View all Survodutide forum discussions